Robbie Marcus
Stock Analyst at JP Morgan
(3.92)
# 566
Out of 5,165 analysts
180
Total ratings
55.08%
Success rate
8.24%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Overweight | $415 → $340 | $230.49 | +47.51% | 5 | Feb 19, 2026 | |
| MDT Medtronic | Maintains: Neutral | $105 → $100 | $88.44 | +13.07% | 13 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $135 → $100 | $71.20 | +40.45% | 14 | Feb 5, 2026 | |
| EW Edwards Lifesciences | Upgrades: Overweight | $90 → $100 | $84.27 | +18.67% | 7 | Dec 18, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $82 → $118 | $55.15 | +113.96% | 8 | Dec 16, 2025 | |
| COO The Cooper Companies | Maintains: Neutral | $66 → $78 | $72.05 | +8.26% | 7 | Dec 5, 2025 | |
| HTFL HeartFlow | Maintains: Overweight | $36 → $40 | $22.52 | +77.62% | 2 | Nov 13, 2025 | |
| CNMD CONMED | Maintains: Neutral | $58 → $52 | $37.34 | +39.26% | 8 | Nov 6, 2025 | |
| RXST RxSight | Maintains: Underweight | $8 → $9 | $7.56 | +19.05% | 6 | Nov 6, 2025 | |
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $115 → $100 | $92.52 | +8.08% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $17 | $19.50 | -12.82% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $75 | $67.32 | +11.41% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $12 → $13 | $9.10 | +42.86% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $16 | $16.71 | -4.25% | 3 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $16 | $13.82 | +15.77% | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $15 → $7 | $8.33 | -15.97% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $120 | $70.23 | +70.87% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $17.62 | +104.31% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $349.11 | +27.47% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $482.76 | +39.82% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $8.99 | +44.61% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $29.58 | +35.23% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $72.34 | +24.41% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $23.46 | +113.13% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $1.46 | +447.95% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $338.00 | -26.04% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.20 | +12.90% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $110.71 | +6.58% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $117.53 | +32.73% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $102.93 | -61.14% | 2 | May 5, 2020 |
Insulet
Feb 19, 2026
Maintains: Overweight
Price Target: $415 → $340
Current: $230.49
Upside: +47.51%
Medtronic
Feb 18, 2026
Maintains: Neutral
Price Target: $105 → $100
Current: $88.44
Upside: +13.07%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $135 → $100
Current: $71.20
Upside: +40.45%
Edwards Lifesciences
Dec 18, 2025
Upgrades: Overweight
Price Target: $90 → $100
Current: $84.27
Upside: +18.67%
Inspire Medical Systems
Dec 16, 2025
Maintains: Neutral
Price Target: $82 → $118
Current: $55.15
Upside: +113.96%
The Cooper Companies
Dec 5, 2025
Maintains: Neutral
Price Target: $66 → $78
Current: $72.05
Upside: +8.26%
HeartFlow
Nov 13, 2025
Maintains: Overweight
Price Target: $36 → $40
Current: $22.52
Upside: +77.62%
CONMED
Nov 6, 2025
Maintains: Neutral
Price Target: $58 → $52
Current: $37.34
Upside: +39.26%
RxSight
Nov 6, 2025
Maintains: Underweight
Price Target: $8 → $9
Current: $7.56
Upside: +19.05%
Zimmer Biomet Holdings
Nov 6, 2025
Downgrades: Neutral
Price Target: $115 → $100
Current: $92.52
Upside: +8.08%
Nov 5, 2025
Maintains: Overweight
Price Target: $21 → $17
Current: $19.50
Upside: -12.82%
Oct 31, 2025
Maintains: Neutral
Price Target: $90 → $75
Current: $67.32
Upside: +11.41%
Oct 31, 2025
Maintains: Underweight
Price Target: $12 → $13
Current: $9.10
Upside: +42.86%
Oct 30, 2025
Maintains: Neutral
Price Target: $13 → $16
Current: $16.71
Upside: -4.25%
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $13.82
Upside: +15.77%
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $8.33
Upside: -15.97%
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $70.23
Upside: +70.87%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $17.62
Upside: +104.31%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $349.11
Upside: +27.47%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $482.76
Upside: +39.82%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $8.99
Upside: +44.61%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $29.58
Upside: +35.23%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $72.34
Upside: +24.41%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $23.46
Upside: +113.13%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $1.46
Upside: +447.95%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $338.00
Upside: -26.04%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.20
Upside: +12.90%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $110.71
Upside: +6.58%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $117.53
Upside: +32.73%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $102.93
Upside: -61.14%